AUAUniversity

Advances in ADT Part II: A Guide for Urologists

CME Available: https://auau.auanet.org/node/39385

Release Date: October, 2023

Expiration Date: October, 2024

LEARNING OBJECTIVES

After participating in this educational activity, participants will be able to:

1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC.

2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer.

3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer.

4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer.

5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists.

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Myovant Sciences LTD

Pfizer, Inc.

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice

CME Available: https://auau.auanet.org/node/39292

Release Date: September, 2023

Expiration Date: September, 2024

After participating in this educational activity, participants will be able to:

1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline.

2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer.

3. Define M0 CRPC and the treatment options.

4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC.

5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.

6. Discuss treatment intensification in mHSPC.

7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice.

ACKNOWLEDGEMENTS

This educational series is supported by independent educational grants from:

• Astellas and Pfizer, Inc.

• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

• Lantheus Medical Imaging

• Merck & Co., Inc.

• Pfizer, Inc.

AUA2023 Medical Student Forum

AUA2023: Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide

CME Available: https://auau.auanet.org/node/38322

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent

CME Available: https://auau.auanet.org/node/38312

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Treatment for Hormone Sensitive Prostate Cancer

CME Available: https://auau.auanet.org/node/38703

Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion.

At the conclusion of this activity, participants will be able to:

1. Apply the AUA Clinical Guidelines for Advanced Prostate Cancer for the treatment of HSPC.

2. Summarize the current utilization of treatment intensification in HSCP and apply appropriate treatment intensification in men with HSPC.

3. Describe the current indications, potential benefits and adverse events that may occur with use of doublet and triplet regimens as compared to SOC in HSPC.

4. Identify opportunities for shared care and team-based approaches to offer state-of-the-art evidenced care for HSPC.

5. Facilitate discussions with patients and caregivers to engage them in the HSPC treatment plan.

ACKNOWLEDGEMENT

This educational activity is supported by an independent educational grant from:

Astellas

Pfizer, Inc.

Update Series (2023) Lesson 21: Management of Chronic Pelvic Pain in Men

Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

AUA2023: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

CME Available: https://auau.auanet.org/node/38307

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation

CME Available: https://auau.auanet.org/node/38327

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

AstraZeneca

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: What the General Urologist Should Know about Care of Transgender Patients

CME Available: https://auau.auanet.org/node/38342

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.